Networking Event Series – Biotech toolkit (CSL Behring) – empowered by Innosuisse
Partnering with CSL Behring: our commitment to serious and rare diseases
Join the networking event series “Biotech Toolkit” empowered by Innosuisse and get some deep insights on how to translate ground-breaking science into successful biotech companies.
CSL is a leading research-driven global biotech company that develops and delivers a broad range of innovative lifesaving therapies to treat serious and often rare disorders. CSL continuously seeks to identify and build relationships with various players from across Europe in an effort to identify breakthrough technologies and novel therapeutic modalities that can feed and support the growth of its internal pipeline, and ultimately deliver new medicines to patients with significant unmet needs.
Join us in this event with CSL Behring to hear great stories and lessons learned on successful partnership. You will discover how to connect and engage with CSL, learn about their areas of interest and much more.
Stephan Emmerth, BaseLaunch
CSL Behring: a leading global biotech company focusing on serious and rare disease
Adrian Zuercher, VP Research Europe, and Head Plasma Protein Research
Areas of interest for early-stage collaborations
Samantha Brandler, Director Research External Innovation Europe
Partnering at the clinical stage
Alex Stankovic, Director Global Licensing
Choices & challenges in early capital raises
Stephanie Read, VP Strategy & Business Development
Let’s discuss Research and Innovation with CSL Behring Q&A
Participation is free, however, registration is required before September 22, 2021.